Ribociclib succinate (LEE011) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM for CDK4 and CDK6, respectively, and is over 1,000-fold less potent against CDK1. It selectively inhibits Cdk4/6, showing greater potency against these compared to Cdk1, Cdk2, Cdk5, Cdk7, and Cdk9. LEE011 reduces proliferation in breast cancer cells (MCF-7 and T47D) and induces cell death and G0/G1 phase arrest in nasopharyngeal carcinoma cells (C666-1 and NPC/HK1). It also shows tumor growth reduction in combination with alpelisib in patient-derived xenograft models. Reagent grade, for research purpose.
Usually ships within 24 hours.